Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma
Authors
Keywords
-
Journal
JOURNAL OF PATHOLOGY
Volume 232, Issue 4, Pages 386-390
Publisher
Wiley
Online
2013-11-25
DOI
10.1002/path.4305
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oncostatin M promotes mesenchymal stem cell-stimulated tumor growth through a paracrine mechanism involving periostin and TGFBI
- (2013) Mi Jeong Lee et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Tissue transglutaminase mediates the pro-malignant effects of oncostatin M receptor over-expression in cervical squamous cell carcinoma
- (2013) Maria M Caffarel et al. JOURNAL OF PATHOLOGY
- Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling
- (2013) Malin Lando et al. JOURNAL OF PATHOLOGY
- Stat3-coordinated Lin-28–let-7–HMGA2 and miR-200–ZEB1 circuits initiate and maintain oncostatin M-driven epithelial–mesenchymal transition
- (2013) L Guo et al. ONCOGENE
- Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer
- (2013) N R West et al. ONCOGENE
- Gene network reconstruction reveals cell cycle and antiviral genes as major drivers of cervical cancer
- (2013) Karina L. Mine et al. Nature Communications
- Oncostatin M suppresses oestrogen receptor-α expression and is associated with poor outcome in human breast cancer
- (2012) Nathan R West et al. ENDOCRINE-RELATED CANCER
- Genital human papillomavirus infections: current and prospective therapies
- (2012) M. A. Stanley JOURNAL OF GENERAL VIROLOGY
- Patient-derived tumour xenografts as models for oncology drug development
- (2012) John J. Tentler et al. Nature Reviews Clinical Oncology
- TG2, a novel extracellular protein with multiple functions
- (2011) Zhuo Wang et al. AMINO ACIDS
- Tissue transglutaminase, inflammation, and cancer: how intimate is the relationship?
- (2011) Santosh Kumar et al. AMINO ACIDS
- Treatment of cervical cancer precursors: influence of age, completeness of excision and cone depth on therapeutic failure, and on adverse obstetric outcomes
- (2011) M Arbyn et al. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
- c-MYC Functions as a Molecular Switch to Alter the Response of Human Mammary Epithelial Cells to Oncostatin M
- (2011) C. E. Kan et al. CANCER RESEARCH
- Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma cells is associated with a pro-angiogenic phenotype and increased cell motility and invasiveness
- (2011) David M Winder et al. JOURNAL OF PATHOLOGY
- Functional evidence that Drosha overexpression in cervical squamous cell carcinoma affects cell phenotype and microRNA profiles
- (2011) Balaji Muralidhar et al. JOURNAL OF PATHOLOGY
- Overexpression of a splice variant of oncostatin M receptor beta in human esophageal squamous carcinoma
- (2011) Tasneem Kausar et al. CELLULAR ONCOLOGY
- Rheumatoid arthritis therapy: Advances from bench to bedside
- (2010) Soo-In Choi et al. AUTOIMMUNITY
- Integrative genomic approaches in cervical cancer: implications for molecular pathogenesis
- (2010) Gopeshwar Narayan et al. Future Oncology
- Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas
- (2008) DR Chen et al. JOURNAL OF PATHOLOGY
- Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha
- (2008) Luigi Scotto et al. Molecular Cancer
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started